Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2016, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.
A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dental Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1 and 1 respectively.Dental Pain.
Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Boehringer Ingelheim GmbH
Laboratorios Del Dr Esteve SA
Pacira Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dental Pain Overview 6
Therapeutics Development 7
Pipeline Products for Dental Pain - Overview 7
Dental Pain - Therapeutics under Development by Companies 8
Dental Pain - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Dental Pain - Products under Development by Companies 12
Dental Pain - Companies Involved in Therapeutics Development 13
Boehringer Ingelheim GmbH 13
Laboratorios Del Dr Esteve SA 14
Pacira Pharmaceuticals Inc 15
Teva Pharmaceutical Industries Ltd 16
Dental Pain - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
(celecoxib + tramadol hydrochloride) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
A-100 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AFAP-3 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BI-1026706 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
bupivacaine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
funapide - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Dental Pain - Dormant Projects 36
Dental Pain - Discontinued Products 38
Dental Pain - Product Development Milestones 39
Featured News & Press Releases 39
Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac 39
Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42
List of Tables
Number of Products under Development for Dental Pain, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Dental Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016 13
Dental Pain - Pipeline by Laboratorios Del Dr Esteve SA, H2 2016 14
Dental Pain - Pipeline by Pacira Pharmaceuticals Inc, H2 2016 15
Dental Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Assessment by Combination Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Dental Pain - Dormant Projects, H2 2016 36
Dental Pain - Dormant Projects (Contd..1), H2 2016 37
Dental Pain - Discontinued Products, H2 2016 38
List of Figures
Number of Products under Development for Dental Pain, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Top 10 Targets, H2 2016 19
Number of Products by Stage and Top 10 Targets, H2 2016 19
Number of Products by Top 10 Mechanism of Actions, H2 2016 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25
